Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7865)
All Articles published online
|
Publishing Process of This Article
|
Jun 7, 2016 (publication date) through Jul 26, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Hu PH, Pan LH, Wong PTY, Chen WH, Yang YQ, Wang H, Xiang JJ, Xu M. 125I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma. World J Gastroenterol 2016; 22(21): 5033-5041 [PMID: 27275095 DOI: 10.3748/wjg.v22.i21.5033] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v22/i21/5033.htm |
| Number | Citing Articles |
| 1 |
Penghui Hu, Kaman So, Hongjie Chen, Qimou Lin, Meng Xu, Yiguang Lin. A monoclonal antibody against basic fibroblast growth factor attenuates cisplatin resistance in lung cancer by suppressing the epithelial-mesenchymal transition. International Journal of Immunopathology and Pharmacology 2022; 36: 039463202211051 doi: 10.1177/03946320221105134
|
| 2 |
Jiaming Zhou, Jiaxuan Liu, Tiejun Li, Qiang Zhong, Hongyu Yu. Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion
and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK
Signaling Pathway. Current Cancer Drug Targets 2024; 24(8): 791 doi: 10.2174/0115680096254722231025110912
|
| 3 |
Penghui Hu, Hongjie Chen, Eileen M McGowan, Nina Ren, Meng Xu, Yiguang Lin. Assessment of FGFR1 Over-Expression and Over-Activity in Lung Cancer Cells: A Toolkit for Anti-FGFR1 Drug Screening. Human Gene Therapy Methods 2018; 29(1): 30 doi: 10.1089/hgtb.2017.104
|
| 4 |
Julie Bolcaen, Shankari Nair, Cathryn Driver, Tebatso Boshomane, Thomas Ebenhan, Charlot Vandevoorde. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. Pharmaceuticals 2021; 14(7): 626 doi: 10.3390/ph14070626
|
| 5 |
Arik Bernard Schulze, Georg Evers, Andrea Kerkhoff, Michael Mohr, Christoph Schliemann, Wolfgang E. Berdel, Lars Henning Schmidt. Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. Cancers 2019; 11(5): 690 doi: 10.3390/cancers11050690
|
| 6 |
Christopher Montemagno, Gilles Pagès. Resistance to Anti-angiogenic Therapies: A Mechanism Depending on the Time of Exposure to the Drugs. Frontiers in Cell and Developmental Biology 2020; 8 doi: 10.3389/fcell.2020.00584
|